Summary
A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder cancer are significantly improved by adding an immunotherapy drug to before and after surgery.
Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer (24 September 2024)
https://www.nejm.org/doi/full/10.1056/NEJMoa2408154
0
reactions so far
0 Comments
Recommended Comments
There are no comments to display.
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now